cagrilintide and semaglutide 2.4 mg Efficacy safety of co-administered once-weekly 2·4 with once-weekly 2·4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial Cagrilintide and Semaglutide: CagriSema Weight

However, some patients might experience mild side effects during their weight loss journey, such as dizziness, nausea, vomiting, upset stomach, diarrhea, tiredness and constipation

After 1 year without the medication, those in the obesity group regained an average of 0.5% of body weight, and those in the diabetes group lost an additional 1.3% of body weight on average

These secondary effects, such as gut microbiome dysbiosis, reduced diversity, and barrier compromise, may offset the anti-inflammatory effects of these medications

Glucose-independent b

AA: Conceptualization, Data curation, Methodology, Validation, Writing original draft